Gene test may personalize Beta-Blocker dosing for heart failure

NCT ID NCT07490067

Recruiting now Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study looks at whether a person's genetic makeup can predict how well they respond to the heart failure drug metoprolol. Researchers will give the drug to 100 people with heart failure and track their heart function and drug levels. The goal is to see if a genetic score can help doctors tailor beta-blocker doses for better results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metoprolol succinate (a beta-blocker drug)
What this could lead to: If successful, this could help doctors use a person's genetic score to choose the best beta-blocker dose for heart failure, making treatment more effective.
What could go wrong: This is a small, early-phase study (100 people) focused on understanding genetics, not proving a new treatment works. The genetic score may not reliably predict responses in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Genetic Risk Score heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.